156 related articles for article (PubMed ID: 16736005)
21. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
Delgado-Enciso I; Cervantes-García D; Martínez-Dávila IA; Ortiz-López R; Alemany-Bonastre R; Silva-Platas CI; Lugo-Trampe A; Barrera-Saldaña HA; Galván-Salazar HR; Coronel-Tene CG; Sánchez-Santillán CF; Rojas-Martínez A
J Gene Med; 2007 Oct; 9(10):852-61. PubMed ID: 17729237
[TBL] [Abstract][Full Text] [Related]
22. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma.
Zhu ZB; Chen Y; Makhija SK; Lu B; Wang M; Rivera AA; Yamamoto M; Wang S; Siegal GP; Curiel DT; McDonald JM
Int J Oncol; 2006 Nov; 29(5):1319-29. PubMed ID: 17016667
[TBL] [Abstract][Full Text] [Related]
23. Role of heat treatment in childhood cancers: distinct resistance profiles of solid tumor cell lines towards combined thermochemotherapy.
Debes A; Willers R; Göbel U; Wessalowski R
Pediatr Blood Cancer; 2005 Oct; 45(5):663-9. PubMed ID: 15929134
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma.
Lamfers ML; Idema S; Bosscher L; Heukelom S; Moeniralm S; van der Meulen-Muileman IH; Overmeer RM; van der Valk P; van Beusechem VW; Gerritsen WR; Vandertop WP; Dirven CM
Clin Cancer Res; 2007 Dec; 13(24):7451-8. PubMed ID: 18094429
[TBL] [Abstract][Full Text] [Related]
25. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma.
Sonabend AM; Ulasov IV; Tyler MA; Rivera AA; Mathis JM; Lesniak MS
Stem Cells; 2008 Mar; 26(3):831-41. PubMed ID: 18192232
[TBL] [Abstract][Full Text] [Related]
26. [Adenovirus-delivered tissue inhibitor of metalloproteinases-3 transfection increases the sensitivity of cervical cancer cells to cisplatin].
Zhang Y; Lin C; Qian HL; Lang JH; Fu M; Zhang XY; Liang X; Duan H; Xiang Y
Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):25-9. PubMed ID: 17575689
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S
Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388
[TBL] [Abstract][Full Text] [Related]
28. Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles.
Ochi K; Daigo Y; Katagiri T; Nagayama S; Tsunoda T; Myoui A; Naka N; Araki N; Kudawara I; Ieguchi M; Toyama Y; Toguchida J; Yoshikawa H; Nakamura Y
Int J Oncol; 2004 Mar; 24(3):647-55. PubMed ID: 14767549
[TBL] [Abstract][Full Text] [Related]
29. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.
Yang C; Hornicek FJ; Wood KB; Schwab JH; Mankin H; Duan Z
Cancer Chemother Pharmacol; 2009 Aug; 64(3):607-14. PubMed ID: 19125251
[TBL] [Abstract][Full Text] [Related]
30. Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma.
Nathan SS; DiResta GR; Casas-Ganem JE; Hoang BH; Sowers R; Yang R; Huvos AG; Gorlick R; Healey JH
Clin Cancer Res; 2005 Mar; 11(6):2389-97. PubMed ID: 15788690
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the protective effects of all-trans-astaxanthin on canine osteosarcoma cell lines.
Wakshlag JJ; Balkman CA; Morgan SK; McEntee MC
Am J Vet Res; 2010 Jan; 71(1):89-96. PubMed ID: 20043787
[TBL] [Abstract][Full Text] [Related]
32. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
[TBL] [Abstract][Full Text] [Related]
33. Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.
Hoffmann D; Bangen JM; Bayer W; Wildner O
Gene Ther; 2006 Nov; 13(21):1534-44. PubMed ID: 16791286
[TBL] [Abstract][Full Text] [Related]
34. A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
Cafferata EG; Macció DR; Lopez MV; Viale DL; Carbone C; Mazzolini G; Podhajcer OL
Clin Cancer Res; 2009 May; 15(9):3037-49. PubMed ID: 19336523
[TBL] [Abstract][Full Text] [Related]
35. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs.
Verheul HM; Qian DZ; Carducci MA; Pili R
Cancer Chemother Pharmacol; 2007 Aug; 60(3):329-39. PubMed ID: 17256134
[TBL] [Abstract][Full Text] [Related]
36. Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.
Siurala M; Bramante S; Vassilev L; Hirvinen M; Parviainen S; Tähtinen S; Guse K; Cerullo V; Kanerva A; Kipar A; Vähä-Koskela M; Hemminki A
Int J Cancer; 2015 Feb; 136(4):945-54. PubMed ID: 24975392
[TBL] [Abstract][Full Text] [Related]
37. A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor.
Carette JE; Graat HC; Schagen FH; Mastenbroek DC; Rots MG; Haisma HJ; Groothuis GM; Schaap GR; Bras J; Kaspers GJ; Wuisman PI; Gerritsen WR; van Beusechem VW
Virology; 2007 Apr; 361(1):56-67. PubMed ID: 17184803
[TBL] [Abstract][Full Text] [Related]
38. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K
Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615
[TBL] [Abstract][Full Text] [Related]
39. Cell-cycle progression and response of germ cell tumors to cisplatin in vitro.
Mueller S; Schittenhelm M; Honecker F; Malenke E; Lauber K; Wesselborg S; Hartmann JT; Bokemeyer C; Mayer F
Int J Oncol; 2006 Aug; 29(2):471-9. PubMed ID: 16820891
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment with 5-FU enhances cisplatin cytotoxicity in head and neck squamous cell carcinoma cells.
Ijichi K; Adachi M; Hasegawa Y; Ogawa T; Nakamura H; Kudoh A; Yasui Y; Murakami S; Ishizaki K
Cancer Chemother Pharmacol; 2008 Oct; 62(5):745-52. PubMed ID: 18075740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
